Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference
Moleculin Biotech's CEO Walter Klemp presented promising interim results from the pivotal Phase 2/3 MIRACLE trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML). The presentation emphasized the drug's differentiated clinical profile, ongoing enrollment, expanding commercial potential, and an upcoming interim analysis of 90 pat…